JPS649292B2 - - Google Patents
Info
- Publication number
- JPS649292B2 JPS649292B2 JP61203565A JP20356586A JPS649292B2 JP S649292 B2 JPS649292 B2 JP S649292B2 JP 61203565 A JP61203565 A JP 61203565A JP 20356586 A JP20356586 A JP 20356586A JP S649292 B2 JPS649292 B2 JP S649292B2
- Authority
- JP
- Japan
- Prior art keywords
- artificial
- surfactant
- mol
- pulmonary
- dipalmitoylphosphatidylcholine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003580 lung surfactant Substances 0.000 claims abstract description 58
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims abstract description 15
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000002950 deficient Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 31
- 239000000596 artificial lung surfactant Substances 0.000 claims description 22
- 239000002502 liposome Substances 0.000 claims description 20
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 11
- 229940083466 soybean lecithin Drugs 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000009469 supplementation Effects 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 abstract description 4
- 239000008347 soybean phospholipid Substances 0.000 abstract description 3
- 229940066294 lung surfactant Drugs 0.000 description 21
- 239000000126 substance Substances 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 230000006835 compression Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000010408 film Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000001698 pyrogenic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000000203 Hyaline Membrane Disease Diseases 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010017740 Gas poisoning Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 241000153444 Verger Species 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000222 hyperoxic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/88—Ampholytes; Electroneutral compounds
- C11D1/886—Ampholytes containing P
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/829—Liposomes, e.g. encapsulation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
- Y10S516/01—Wetting, emulsifying, dispersing, or stabilizing agents
- Y10S516/06—Protein or carboxylic compound containing
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8512950A FR2586587B1 (fr) | 1985-08-30 | 1985-08-30 | Nouveaux surfactants artificiels, leur preparation et les compositions pharmaceutiques qui les contiennent. |
| FR8512950 | 1985-08-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6296425A JPS6296425A (ja) | 1987-05-02 |
| JPS649292B2 true JPS649292B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-02-16 |
Family
ID=9322508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61203565A Granted JPS6296425A (ja) | 1985-08-30 | 1986-08-29 | 人工の、肺表面活性剤及びそれを含有する医薬組成物 |
Country Status (6)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256569A (en) * | 1986-01-21 | 1993-10-26 | Chisso Corporation | Transesterification process for otereoselection of enantiomers of secondary alcohols using pseudomonas lipase with no added solvent |
| US5032585A (en) * | 1987-02-17 | 1991-07-16 | Board Of Regents, The University Of Texas System | Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
| IT1203873B (it) * | 1987-04-08 | 1989-02-23 | Chiesi Farma Spa | Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e |
| US4921644A (en) * | 1988-02-29 | 1990-05-01 | Technology Unlimited, Inc. | Mucin directed lipsome |
| CA1335348C (en) * | 1988-03-04 | 1995-04-25 | Yasuaki Ogawa | Liposome composition |
| US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
| US4935171A (en) * | 1989-01-27 | 1990-06-19 | Vestar, Inc. | Method for vesicle formation |
| US5207220A (en) * | 1989-12-12 | 1993-05-04 | Burroughs Wellcome Co. | Method for administering pharmaceuticals, including liquid surfactant, to the lungs |
| FR2658418B1 (fr) * | 1990-02-20 | 1994-09-02 | Synthelabo | Compositions pharmaceutiques a base de phospholipides. |
| DE4107153A1 (de) * | 1991-03-06 | 1992-09-10 | Gregor Cevc | Praeparat zur wirkstoffapplikation in kleinsttroepfchenform |
| DE4107152C2 (de) * | 1991-03-06 | 1994-03-24 | Gregor Cevc | Präparate zur nichtinvasiven Verabreichung von Antidiabetica |
| US5614216A (en) * | 1990-10-17 | 1997-03-25 | The Liposome Company, Inc. | Synthetic lung surfactant |
| GB2250998A (en) * | 1990-12-21 | 1992-06-24 | Unilever Plc | Cosmetic cleansing composition |
| US5272252A (en) * | 1991-11-04 | 1993-12-21 | Merrell Dow Pharmaceuticals Inc. | Synthetic lung surfactant having antioxidant properties |
| US5319116A (en) * | 1992-02-12 | 1994-06-07 | Gary Viole | Lecithin fractions and dilutions, methods for their preparation and pharmacological uses thereof |
| US6129934A (en) * | 1995-06-07 | 2000-10-10 | Ony, Inc. | Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction |
| US5698537A (en) * | 1996-06-18 | 1997-12-16 | Clarion Pharmaceuticals Inc. | Method of lowering the viscosity of mucus |
| US6565885B1 (en) | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US20020017295A1 (en) * | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| US6156294A (en) | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| US8404217B2 (en) | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| EP1280520B2 (en) * | 2000-05-10 | 2018-03-21 | Novartis AG | Phospholipid-based powders for drug delivery |
| ES2346048T3 (es) * | 2001-10-11 | 2010-10-08 | Nycomed Gmbh | Nueva utilizacion de un agente tensioactivo pulmonar. |
| WO2003053411A1 (en) * | 2001-12-19 | 2003-07-03 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
| WO2007001094A1 (ja) * | 2005-06-29 | 2007-01-04 | Sannamu Lee | 人工肺サーファクタント組成物 |
| EP3291818B1 (en) * | 2015-05-04 | 2019-10-30 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for delivering therapeutic agents into the colon |
| WO2025045767A1 (en) * | 2023-08-25 | 2025-03-06 | Ethris Gmbh | Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2900300A1 (de) * | 1979-01-05 | 1980-07-17 | Lebrecht Von Dr Klitzing | Verfahren einer prophylaxe zur vermeidung des atemnotsyndroms bei fruehgeborenen und bei der schocklunge |
| US4310506A (en) * | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
| US4312860A (en) * | 1980-10-24 | 1982-01-26 | Regents Of The University Of California | Lung surfactant compositions |
| US4394372A (en) * | 1980-12-22 | 1983-07-19 | The Procter & Gamble Company | Process for making lipid membrane structures |
| DE3369644D1 (en) * | 1982-11-22 | 1987-03-12 | Teijin Ltd | Artificial lung surfactant and remedy for respiratory distress syndrome containing it as active principle |
| US4515736A (en) * | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
| JPS6150912A (ja) * | 1984-08-16 | 1986-03-13 | Shionogi & Co Ltd | リポソ−ム製剤の製造法 |
-
1985
- 1985-08-30 FR FR8512950A patent/FR2586587B1/fr not_active Expired
-
1986
- 1986-08-25 US US06/899,656 patent/US4765987A/en not_active Expired - Fee Related
- 1986-08-29 EP EP86401896A patent/EP0214055B1/fr not_active Expired
- 1986-08-29 JP JP61203565A patent/JPS6296425A/ja active Granted
- 1986-08-29 AT AT86401896T patent/ATE48946T1/de not_active IP Right Cessation
- 1986-08-29 DE DE8686401896T patent/DE3667749D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE3667749D1 (de) | 1990-02-01 |
| EP0214055A1 (fr) | 1987-03-11 |
| US4765987A (en) | 1988-08-23 |
| ATE48946T1 (de) | 1990-01-15 |
| JPS6296425A (ja) | 1987-05-02 |
| EP0214055B1 (fr) | 1989-12-27 |
| FR2586587B1 (fr) | 1987-10-23 |
| FR2586587A1 (fr) | 1987-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS649292B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| US4312860A (en) | Lung surfactant compositions | |
| JP2700323B2 (ja) | 肺動脈界面活性剤、その調製方法、及び薬剤組成物 | |
| KR100454377B1 (ko) | 약제전달을위한연속플루오로화합물미립분산액 | |
| US4826821A (en) | Lung surfactant compositions | |
| JP3074733B2 (ja) | 脂肪乳剤 | |
| US7842664B2 (en) | Synthetic lipid mixtures for the preparation of a reconstituted surfactant | |
| EP0469082B1 (en) | Liposomal targeting of ischemic tissue | |
| US5110806A (en) | Lung surfactant compositions | |
| US20100317636A1 (en) | Reducing the risk of chronic lung disease in infants | |
| JP3103582B2 (ja) | 低粘度、高濃度サーファクタント懸濁液 | |
| JP5638204B2 (ja) | 経口投与用リポソーム製剤およびその製造方法 | |
| CN1256949C (zh) | 三七总皂苷脂质体及其制备方法 | |
| WO1980001456A1 (en) | Pharmaceutical composition and process for the preparation thereof | |
| JP3376582B2 (ja) | 合成ペプチド、それを含有する肺サーファクタント及び呼吸窮迫症候群治療剤 | |
| JPH11509843A (ja) | 連続フッ素化相からなるリバースゲル | |
| JPH10245346A (ja) | リポソーマル人カルシトニン遺伝子関係ペプチド組成物及びその製造方法 | |
| JPH06502427A (ja) | 合成肺表面活性剤 | |
| JP2023523033A (ja) | 自己組織化する酸素キャリアー組成物 | |
| KR960013436B1 (ko) | 천연 폐 계면활성제, 그의 제조방법 및 이것을 함유하는 제약 조성물 | |
| JPS6165821A (ja) | 合成サ−フアクタント及びそれを有効成分とする肺表面活性物質喪失性無気肺の治療剤 | |
| JPS5995219A (ja) | 合成肺表面活性物質及びそれを有効成分とする呼吸窮迫症候群治療剤 | |
| HK1079221B (en) | Improved synthetic lipid mixtures for the preparation of a reconstituted surfactant | |
| AU6651100A (en) | Continuous fluorochemical microdispersions for the delivery of pharmaceutical agents |